Ready to start your weight loss journey with expert medical guidance and individualized support
In the major clinical trials, participants taking tirzepatide saw an average weight loss of 15% to 22.5% of their starting body weight over 72 weeks
doi: 10.1016/j.mito.2019.02.002
[15] [16] This peptide demonstrated remarkable glucose-lowering properties, leading to the development of exenatide (Byetta), the first GLP-1 receptor agonist approved for diabetes treatment in the mid-2000s (receiving European approval in 2006)
Large observational studies now indicate that it may also reduce the risk of depression, anxiety, self-harm, and addiction-related harms, with semaglutide showing especially strong signals in several measures
Give yourself the advantage of changing your lifestyle to accommodate and incentivize your resolution